Literature DB >> 7588203

11 beta-hydroxysteroid dehydrogenase is an exclusive 11 beta- reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations.

P M Jamieson1, K E Chapman, C R Edwards, J R Seckl.   

Abstract

11 beta-Hydroxysteroid dehydrogenase (11 beta HSD) catalyzes the conversion of corticosterone to inert 11-dehydrocorticosterone, thus regulating glucocorticoid access to intracellular receptors. This type 1 isoform (11 beta HSD-1) is a bidirectional NADPH(H)-dependent enzyme in vitro and is highly expressed in liver, where it is regulated by glucocorticoids, thyroid hormones, estrogen, and GH in vivo. In humans in vivo, enzyme inhibition alters glucose homeostasis, an effect thought to be mediated in the liver. However, detailed investigation of the biology of 11 beta HSD-1 in liver, its function, regulation, and indeed even reaction direction, has been hampered by the lack of clonal hepatic cell lines that express 11 beta HSR-1. Studies of nonhepatic cell lines have suggested that 11 beta HSD-1 is directly regulated by hormones, and transfection of nonhepatic cell lines has sown that reaction direction varies between cell types, possibly reflecting intracellular cosubstrate (NADP+/NADPH) ratios or PH. To investigate reaction direction and gene regulation of 11 beta HSD-1 in hepatocytes, we defined conditions for primary culture of adult rat hepatocytes that maintain high 11 beta HSR-1 messenger RNA expression. In intact primary hepatocytes over a wide range of steroid concentrations (2.5-250 nM), 11 beta-reduction was the predominant reaction direction [33.5 +/- 0.5% conversion of 11-dehydrocorticosterone (25 nM) to corticosterone after 30 min], with undetectable 11 beta-dehydrogenation. However, homogenates of hepatocyte cultures showed plentiful 11 beta-dehydrogenase activity. Treatment of hepatocyte cultures with the metabolic inhibitors sodium azide (5 nM) and KCN (1 nM) altered cellular NADP+/NADPH ratios from 0.244 +/- 0.042 in controls to 0.020 +/- 0.001 and 0.152 +/- 0.009, respectively, but had no effect on 11 beta-reductase or 11 beta- dehydrogenase activity. High concentrations of KCN (10 mM) modestly increased 11 beta-reductase activity (32.4 +/- 1.7% to 48.8 +/- 0.5%, whereas 11 beta-dehydrogenation remained at the limit of detection. Manipulation of culture medium pH (6.2-8.0) had no effect on enzyme activity. Dexamethasone (10-7 M) induced hepatocyte 11 beta-reductase activity from 23.4 +/- 0.7% to only weakly affects reaction direction. Glucocorticoid and insulin regulation of hepatic 11 beta HSD-1 is directly mediated, but other hormonal controls are either lost in culture or mediated indirectly. This primary hepatocyte culture system will allow investigation of the control of 11 beta-reductase activity and its implications for glucocorticoid-regulated hepatic functions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7588203     DOI: 10.1210/endo.136.11.7588203

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  52 in total

1.  Reciprocal regulation of 11β-hydroxysteroid dehydrogenase 1 and glucocorticoid receptor expression by dexamethasone inhibits human coronary artery smooth muscle cell proliferation in vitro.

Authors:  George Michas; Marcel Liberman; Kristian C Becker; Diane E Handy; Joseph Loscalzo; Jane A Leopold
Journal:  Mol Cell Biochem       Date:  2010-10-05       Impact factor: 3.396

2.  Lack of tissue glucocorticoid reactivation in 11beta -hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments.

Authors:  J L Yau; J Noble; C J Kenyon; C Hibberd; Y Kotelevtsev; J J Mullins; J R Seckl
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

3.  Activities of aldo-keto reductase 1 enzymes on two inhaled corticosteroids: implications for the pharmacological effects of inhaled corticosteroids.

Authors:  Yi Jin
Journal:  Chem Biol Interact       Date:  2011-01-27       Impact factor: 5.192

4.  Labisia pumila extract down-regulates hydroxysteroid (11-beta) dehydrogenase 1 expression and corticosterone levels in ovariectomized rats.

Authors:  Mansor Fazliana; Harvest F Gu; Claes-Göran Östenson; Mashitah Mohd Yusoff; W M Wan Nazaimoon
Journal:  J Nat Med       Date:  2011-08-11       Impact factor: 2.343

Review 5.  11beta-HSD1, inflammation, metabolic disease and age-related cognitive (dys)function.

Authors:  Karen E Chapman; Jonathan R Seckl
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

6.  Annexin 1 (lipocortin 1) mimics inhibitory effects of glucocorticoids on testosterone secretion and enhances effects of interleukin-1beta.

Authors:  Patricia O Cover; Frederick Baanah-Jones; Christopher D John; Julia C Buckingham
Journal:  Endocrine       Date:  2002-06       Impact factor: 3.633

Review 7.  Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.

Authors:  Patrick W F Hadoke; Javaid Iqbal; Brian R Walker
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

8.  Hepatic 11β-hydroxysteroid dehydrogenase type 1 activity in obesity and type 2 diabetes using a novel triple tracer cortisol technique.

Authors:  Simmi Dube; Barbara Norby; Vishwanath Pattan; Ravi K Lingineni; Ravinder J Singh; Rickey E Carter; Ananda Basu; Rita Basu
Journal:  Diabetologia       Date:  2014-04-26       Impact factor: 10.122

9.  Liver is the site of splanchnic cortisol production in obese nondiabetic humans.

Authors:  Rita Basu; Ananda Basu; Meagan Grudzien; Paul Jung; Peer Jacobson; Michael Johnson; Ravinder Singh; Michael Sarr; Robert A Rizza
Journal:  Diabetes       Date:  2008-10-13       Impact factor: 9.461

10.  11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics.

Authors:  Thekkepat C Sandeep; Joyce L W Yau; Alasdair M J MacLullich; June Noble; Ian J Deary; Brian R Walker; Jonathan R Seckl
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.